Qiagen NV (NYSE: QGEN) has a price-to-earnings ratio of 102.65x that is above its average ratio. Additionally, the 36-month beta value for QGEN is 0.34. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for QGEN is 221.24M and currently, short sellers hold a 1.61% ratio of that float. The average trading volume of QGEN on November 15, 2024 was 1.18M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
QGEN) stock’s latest price update
The stock price of Qiagen NV (NYSE: QGEN) has dropped by -1.54 compared to previous close of 42.09. Despite this, the company has seen a fall of -5.30% in its stock price over the last five trading days. zacks.com reported 2024-11-13 that QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health.
QGEN’s Market Performance
QGEN’s stock has fallen by -5.30% in the past week, with a monthly drop of -2.93% and a quarterly drop of -11.74%. The volatility ratio for the week is 1.50% while the volatility levels for the last 30 days are 1.51% for Qiagen NV The simple moving average for the past 20 days is -2.89% for QGEN’s stock, with a -4.63% simple moving average for the past 200 days.
Analysts’ Opinion of QGEN
Many brokerage firms have already submitted their reports for QGEN stocks, with HSBC Securities repeating the rating for QGEN by listing it as a “Hold.” The predicted price for QGEN in the upcoming period, according to HSBC Securities is $49 based on the research report published on October 17, 2024 of the current year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see QGEN reach a price target of $50. The rating they have provided for QGEN stocks is “Outperform” according to the report published on June 27th, 2024.
Wells Fargo gave a rating of “Equal Weight” to QGEN, setting the target price at $44 in the report published on December 19th of the previous year.
QGEN Trading at -5.49% from the 50-Day Moving Average
After a stumble in the market that brought QGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.65% of loss for the given period.
Volatility was left at 1.51%, however, over the last 30 days, the volatility rate increased by 1.50%, as shares sank -3.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.77% lower at present.
During the last 5 trading sessions, QGEN fell by -5.23%, which changed the moving average for the period of 200-days by -6.03% in comparison to the 20-day moving average, which settled at $42.67. In addition, Qiagen NV saw -4.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QGEN starting from Sackers Roland, who proposed sale 25,000 shares at the price of $46.00 back on Sep 11 ’24. After this action, Sackers Roland now owns shares of Qiagen NV, valued at $1,150,000 using the latest closing price.
Stock Fundamentals for QGEN
Current profitability levels for the company are sitting at:
- 0.05 for the present operating margin
- 0.5 for the gross margin
The net margin for Qiagen NV stands at 0.04. The total capital return value is set at 0.02. Equity return is now at value 2.57, with 1.53 for asset returns.
Based on Qiagen NV (QGEN), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at 0.41. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is 2.17.
Currently, EBITDA for the company is 650.58 million with net debt to EBITDA at 2.6. When we switch over and look at the enterprise to sales, we see a ratio of 5.19. The receivables turnover for the company is 5.26for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.17.
Conclusion
In conclusion, Qiagen NV (QGEN) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
